Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 75 versus XTAMPZA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 75 versus XTAMPZA ER.
DURAGESIC-75 vs XTAMPZA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent opioid agonist primarily at the mu-opioid receptor, exerting its analgesic effects by mimicking endogenous endorphins and enkephalins to activate G-protein-coupled inwardly rectifying potassium channels, leading to hyperpolarization and reduced neuronal excitability in pain pathways.
Oxycodone is a full mu-opioid receptor agonist, producing analgesia, euphoria, and sedation. Xtampza ER utilizes DETERx technology to provide extended-release properties and resist tampering.
Adults: Apply one 75 mcg/hr transdermal patch every 72 hours. Start with lower dose in opioid-naive patients.
Initial: 9 mg orally every 12 hours with food; titrate by 9 mg every 3-7 days as needed; maximum dose: 36 mg every 12 hours.
None Documented
None Documented
22-25 hours after removal of patch; increased in elderly, hepatic/renal impairment
3-4 hours for immediate-release morphine; 8-12 hours for extended-release formulation (XTAMPZA ER), allowing twice-daily dosing
Renal (75% as metabolites, <10% unchanged), fecal (25%)
Primarily renal (70-90% as morphine-3-glucuronide, morphine-6-glucuronide, and free morphine); biliary/fecal (10-20%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic